Key Takeaways
- • ARK Investment Management purchased 553,892 shares of Robinhood Markets (NASDAQ:HOOD) valued at approximately $45.5 million on April 29, 2026, continuing aggressive accumulation in the fintech platform across its three actively managed ETFs.
- • ARK divested 243,147 shares of its own ARK 21Shares Bitcoin ETF (BATS:ARKB), selling approximately $1.35 million worth, signaling a tactical shift in cryptocurrency exposure positioning.
- • Additional ARK acquisitions on the same trading day included 2.4 million shares of Intellia Therapeutics ($31.8 million) and 191,174 shares of Kratos Defense ($11.8 million), reflecting continued focus on biotechnology and defense technology sectors.
- • Robinhood has become a core strategic holding for ARK's flagship funds, with the fintech company representing a significant position across ARKK, ARKW, and ARKF ETFs as of late April 2026.
- • The trading activity reflects ARK's portfolio rebalancing amid evolving market conditions, with selective profit-taking in cryptocurrency exposure offset by conviction purchases in technology and innovation-focused equities.
Summary
Cathie Wood's ARK Investment Management executed a substantial investment in Robinhood Markets on April 29, 2026, acquiring 553,892 shares valued at approximately $45.5 million. The purchase was distributed across ARK's three actively managed exchange-traded funds, with the bulk allocated to the ARK Innovation ETF (ARKK), while smaller positions were added to the ARK Next Generation Internet ETF (ARKW) and ARK Fintech Innovation ETF (ARKF). This transaction represents a continuation of ARK's strategic focus on the retail trading and financial services platform, reinforcing Robinhood's prominence within the firm's innovation-themed portfolio.
Concurrent with the Robinhood purchase, ARK executed a notable divestment in its own spot bitcoin ETF product, selling 243,147 shares of the ARK 21Shares Bitcoin ETF (BATS:ARKB) for approximately $1.35 million. This tactical reduction in direct cryptocurrency exposure, while simultaneously building fintech equity positions, signals a recalibration in how ARK is accessing digital asset market participation—shifting weight from direct spot bitcoin holdings toward cryptocurrency-adjacent equities that offer leveraged exposure to blockchain infrastructure and digital asset platforms.
The broader trading activity on April 29 demonstrated ARK's continued conviction in biotechnology and defense innovation sectors. The firm acquired 2.4 million shares of Intellia Therapeutics Inc. (NASDAQ:NTLA) across ARKK and ARKG funds for $31.8 million, building on prior week purchases. ARK also invested $11.8 million in Kratos Defense and Security Solutions Inc. (NASDAQ:KTOS), purchasing 191,174 shares through ARKK. Concurrently, ARK trimmed select biotech positions, selling 63,000 shares of Twist Bioscience Corp. (NASDAQ:TWST) for $3.7 million through its genomics-focused ARKG ETF.
These transactions underscore ARK's dynamic portfolio management approach: maintaining core convictions in disruptive technology categories while executing tactical profit-taking and rebalancing. The substantial Robinhood position reflects confidence in the brokerage's structural positioning within digital asset adoption and fintech innovation, even as ARK adjusts its direct cryptocurrency asset allocation. The pattern of activity on April 29 aligns with broader institutional investor behavior in 2026—rotating between different risk exposures within the innovation ecosystem while selectively taking profits on high-conviction thesis positions that have appreciated significantly.
Concurrent with the Robinhood purchase, ARK executed a notable divestment in its own spot bitcoin ETF product, selling 243,147 shares of the ARK 21Shares Bitcoin ETF (BATS:ARKB) for approximately $1.35 million. This tactical reduction in direct cryptocurrency exposure, while simultaneously building fintech equity positions, signals a recalibration in how ARK is accessing digital asset market participation—shifting weight from direct spot bitcoin holdings toward cryptocurrency-adjacent equities that offer leveraged exposure to blockchain infrastructure and digital asset platforms.
The broader trading activity on April 29 demonstrated ARK's continued conviction in biotechnology and defense innovation sectors. The firm acquired 2.4 million shares of Intellia Therapeutics Inc. (NASDAQ:NTLA) across ARKK and ARKG funds for $31.8 million, building on prior week purchases. ARK also invested $11.8 million in Kratos Defense and Security Solutions Inc. (NASDAQ:KTOS), purchasing 191,174 shares through ARKK. Concurrently, ARK trimmed select biotech positions, selling 63,000 shares of Twist Bioscience Corp. (NASDAQ:TWST) for $3.7 million through its genomics-focused ARKG ETF.
These transactions underscore ARK's dynamic portfolio management approach: maintaining core convictions in disruptive technology categories while executing tactical profit-taking and rebalancing. The substantial Robinhood position reflects confidence in the brokerage's structural positioning within digital asset adoption and fintech innovation, even as ARK adjusts its direct cryptocurrency asset allocation. The pattern of activity on April 29 aligns with broader institutional investor behavior in 2026—rotating between different risk exposures within the innovation ecosystem while selectively taking profits on high-conviction thesis positions that have appreciated significantly.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.